127 related articles for article (PubMed ID: 38422881)
1. A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
Sidi Y; Dong C; Wu Y; Faller DV
Leuk Res; 2024 Mar; 138():107465. PubMed ID: 38422881
[TBL] [Abstract][Full Text] [Related]
2. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
Norsworthy KJ; Gao X; Ko CW; Pulte ED; Zhou J; Gong Y; Shen YL; Vallejo J; Gwise TE; Sridhara R; Deisseroth AB; Farrell AT; de Claro RA; Blumenthal GM; Pazdur R
J Clin Oncol; 2022 Mar; 40(8):847-854. PubMed ID: 34890212
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).
Yin J; LaPlant B; Uy GL; Marcucci G; Blum W; Larson RA; Stone RM; Mandrekar SJ
Blood Adv; 2019 Jun; 3(11):1714-1721. PubMed ID: 31171508
[TBL] [Abstract][Full Text] [Related]
4. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
5. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
[TBL] [Abstract][Full Text] [Related]
6. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
7. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
8. Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review.
Shahzad M; Chaudhary SG; Tariq E; Mushtaq AH; Anwar I; Ahmed N; Bansal R; Lutfi F; Balusu R; Abdelhakim H; Yacoub A; Hematti P; Singh AK; McGuirk JP; Mushtaq MU
Leuk Lymphoma; 2023 Feb; 64(2):273-282. PubMed ID: 36282773
[TBL] [Abstract][Full Text] [Related]
9. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Tsimberidou AM; Kantarjian HM; Wen S; Keating MJ; O'Brien S; Brandt M; Pierce S; Freireich EJ; Medeiros LJ; Estey E
Cancer; 2008 Sep; 113(6):1370-8. PubMed ID: 18623376
[TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
11. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
13. Potentiality of Protein phosphatase Mg
Yu M; Hu J; He D; Chen Q; Liu S; Zhu X; Li B
J Clin Lab Anal; 2020 May; 34(5):e23171. PubMed ID: 31901183
[TBL] [Abstract][Full Text] [Related]
14. Statistical considerations in clinical trial design with event-free survival as the primary efficacy endpoint.
Xu T; Zhang Y; Goldwasser M; Zhang V
Pharm Stat; 2021 Jul; 20(4):721-736. PubMed ID: 33594827
[TBL] [Abstract][Full Text] [Related]
15. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
17. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
18. [Treatment failure in children with acute myelocytic leukemia: over 25-year experience of Polish Pediatric Leukemia/Lymphoma Study Group with four consecutive unified treatment protocols for childhood acute myelocytic leukemia].
Dłuzniewska A; Balwierz W; Balcerska A; Chybicka A; Kamieńska E; Karolczyk G; Karpińska-Derda I; Krawczuk-Rybak M; Kowalczyk JR; Lewandowska D; Maciejka-Kapuścińska L; Kołtano S; Malinowska I; Matysiak M; Mikołajczyk M; Mizia-Malarz A; Muszyńska-Rosłan K; Niedźwiedzki M; Pohorecka J; Sikorska-Fic B; Sobol G; Sońta-Jakimczyk D; Tomaszewska R; Urasiński T; Wachowiak J; Wieczorek M; Wójcik B; Wysocki M
Przegl Lek; 2010; 67(6):366-70. PubMed ID: 21344763
[TBL] [Abstract][Full Text] [Related]
19. [Response rate of AML-XH-99 protocol in the treatment of 82 childhood acute myeloid leukemia].
Li J; Gu LJ; Xue HL; Tang JY; Chen J; Zhao HJ; Chen J; Pan C; Wang YP; Ye H
Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):351-4. PubMed ID: 15308014
[TBL] [Abstract][Full Text] [Related]
20. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
